ABEONA THERAPEUTICS INC. (ABEO)
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
Address
6555 CARNEGIE AVE, 4TH FLOOR
CLEVELAND, OH 44103
Founded
1974
Number of Employees
84
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s ) |
- | - | - | - | - | - | - | - | - | $162 | $301 | $232 |
| Average Price | - | - | - | - | - | - | - | - | - | $3.85 | $4.52 | $4.26 |
| # Shares Purchased | - | - | - | - | - | - | - | - | - | 42,083 | 66,683 | 54,383 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | - | - | - | - | - | - | - | 30.0% | 10.6% | 17.4% |
| S&P 500 Return to Date | - | - | - | - | - | - | - | - | - | 31.3% | 7.4% | 19.4% |
| Excess Total Return | - | - | - | - | - | - | - | - | - | -1.3% | 3.2% | -2.0% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | - | - | - | - | - | - | - | 70% | 62% | 54% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at ABEO make a trade.
Creating a free account takes less than one minute